

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures
ML-18 is supplied as a solid. A stock solution may be made by dissolving the ML-18 in the solvent of choice, which should be purged with an inert gas. ML-18 is soluble in the organic solvent DMSO.

## Description

ML-18 is a non-peptide bombesin receptor subtype $3\left(\mathrm{BB}_{3}\right)$ antagonist that inhibits [ ${ }^{125}$ I]BA1 binding to $\mathrm{NCI}-\mathrm{H} 1299$ lung cancer cells transfected with human $\mathrm{BB}_{3}$ receptors $\left(\mathrm{IC}_{50}=4.8 \mu \mathrm{M}\right) .{ }^{1}$ It is selective for $\mathrm{BB}_{3}$ over the gastrin releasing peptide receptor (GRPR) and the neuromedin B receptor (NMBR) with $\mathrm{IC}_{50}$ values of 16 and $>100 \mu \mathrm{M}$, respectively, in a radioligand binding assay. ML-18 (16 $\left.\mu \mathrm{M}\right)$ reversibly inhibits BA1-induced increases in cytosolic calcium in NCI-H1299 cells. It also inhibits BA1-induced phosphorylation of ERK and EGFR and reduces proliferation of $\mathrm{NCI}-\mathrm{H} 1299$ cells.

## Reference

1. Moody, T.W., Mantey, S.A., Moreno, P., et al. ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. Peptides 64, 55-61 (2015).

## WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

## SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

